Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

101. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens Zintzaras E, Dahabreh I J, Giannouli S, Voulgarelis M, Moutsopoulos H M CRD summary This review concluded (...) that infliximab at 10 mg/kg in combination with methotrexate was more effective for the treatment of active rheumatoid arthritis than methotrexate alone or in combined therapy with infliximab at 3 mg/kg, without increased adverse events. This conclusion closely reflected the results of the review but its reliability may be limited by the relative narrowness of the search. Authors' objectives To assess the efficacy and tolerability of infliximab plus methotrexate compared with methotrexate alone

DARE.2008

102. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled (...) trials Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A CRD summary This review assessed the efficacy and safety of alefacept, efalizumab, etanercept and infliximab for treatment of moderate to severe plaque psoriasis and concluded that all treatments yielded significant improvements over placebo in the short term with an increased risk of adverse events. The authors’ conclusions from this generally well-conducted review reflected the evidence and are likely to be reliable. Authors

DARE.2008

103. Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease

Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease Article Text Therapeutics Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s

Evidence-Based Medicine (Requires free registration)2008

104. Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.

Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. OBJECTIVE: To compare the effects of methotrexate (MTX), alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab, on magnetic resonance imaging (MRI)-detected synovitis, bone edema, and erosive changes in patients (...) with early rheumatoid arthritis (RA). METHODS: Forty-four patients with early RA were randomized to receive MTX alone (MTX group), MTX plus IV MP (IV MP group), or MTX plus infliximab (infliximab group), infused on day 0 and weeks 2, 6, 14, 22, 30, 38, and 46. Gadolinium-enhanced MRI scans of the metacarpophalangeal joints, wrists, and metatarsophalangeal joints were performed at baseline, week 18, and week 52. RESULTS: Scores for MRI-detected synovitis and bone edema improved over time in the 3 groups

EvidenceUpdates2008

105. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab.

Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. BACKGROUND: A warning for tuberculosis was added to the approved labeling for infliximab in October 2001. OBJECTIVE: To describe adverse event reports of tuberculosis during infliximab therapy after labeling changes. DESIGN: Case series. SETTING: Spontaneous adverse event reports maintained in the Adverse Event Reporting System database in the United States. PATIENTS: 130 patients (...) with infliximab-associated tuberculosis. MEASUREMENTS: Clinical and laboratory data. RESULTS: The U.S. Food and Drug Administration received 130 domestic, spontaneous reports of tuberculosis in patients treated with infliximab between 1 November 2001 and 30 May 2006, including 59 (45%) with extrapulmonary disease. The most commonly reported risk factors included concomitant immunosuppressant use (n = 89), history of latent or active tuberculosis (n = 33), and being born into or having spent extensive time

Annals of Internal Medicine2007

106. Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please

NIHR HTA programme2007

108. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn`s disease in children

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn`s disease in children BACKGROUND AND AIMS: The REACH study evaluated the safety and efficacy of infliximab in children with moderately to severely active Crohn's disease. METHODS: Patients (n = 112) with a Pediatric Crohn's Disease Activity Index (PCDAI) score >30 received infliximab 5 mg/kg at weeks 0, 2, and 6. Patients responding to treatment at week 10 were randomized to infliximab 5 mg/kg every 8 (...) or 12 weeks through week 46. A concurrent immunomodulator was required. Clinical response (decrease from baseline in the PCDAI score > or =15 points; total score < or =30) and clinical remission (PCDAI score < or =10 points) were evaluated at weeks 10, 30, and 54. RESULTS: At week 10, 99 of 112 (88.4%) patients responded to infliximab (95% confidence interval: [82.5%, 94.3%]) and 66 of 112 (58.9%) patients achieved clinical remission (95% confidence interval: [49.8%, 68.0%]). At week 54, 33

EvidenceUpdates2007

110. Systematic review: infliximab therapy in ulcerative colitis

Systematic review: infliximab therapy in ulcerative colitis Systematic review: infliximab therapy in ulcerative colitis Systematic review: infliximab therapy in ulcerative colitis Gisbert J P, Gonzalez-Lama Y, Mate J CRD summary This review evaluated the efficacy and safety of infliximab in patients with ulcerative colitis (UC). The authors concluded that in patients with moderate-to-severe UC, infliximab is more effective than placebo at approximately 9 months' follow-up; further studies (...) are needed to address long-term effects. These conclusions appear reliable. Authors' objectives To assess the efficacy and tolerability of infliximab administration in patients with ulcerative colitis (UC). Searching The Cochrane Library (Issue 4, 2005), MEDLINE, EMBASE and CINAHL were searched up to January 2006; the search terms were reported. No language restrictions were applied. In addition, ISI Web of Knowledge, bibliographies of retrieved trial reports and reviews, and the conference abstracts

DARE.2007

111. A systematic review of infliximab in the treatment of early rheumatoid arthritis

A systematic review of infliximab in the treatment of early rheumatoid arthritis A systematic review of infliximab in the treatment of early rheumatoid arthritis A systematic review of infliximab in the treatment of early rheumatoid arthritis Du Pan S M, Gabay C, Finckh A CRD summary This review assessed the efficacy and safety of the treatment of early rheumatoid arthritis with infliximab. The authors concluded that infliximab in combination with methotrexate was more efficacious than (...) methotrexate alone. Due to shortcomings in the review, this conclusion may not be reliable. Authors' objectives To assess the efficacy and safety of early rheumatoid arthritis treatment with infliximab. Searching MEDLINE (from 1966), EMBASE (from 1974) and the Cochrane Central Register of Controlled Trials were searched to May 2006. Conference abstracts from the American College of Rheumatology and the European League Against Rheumatism were reviewed from 2004 to 2005. The manufacturers were contacted

DARE.2007

112. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response (...) in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T CRD summary This review compared tumour necrosis factor-alpha blocking drugs for rheumatoid arthritis and concluded that adalimumab, etanercept and infliximab had similar efficacy, but infliximab may need higher doses for a similar effect. Given that this was based on an indirect comparison of only one trial of each

DARE.2007

113. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis | Guidance and guidelines | NICE Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis Technology appraisal guidance [TA130] Published date: 22 October 2007 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2007

114. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis Bravo Vergel Y, Hawkins N S, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce I N, Sculpher M J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared two tumour necrosis factor antagonists, etanercept and infliximab, with palliative care for the treatment of patients with psoriatic arthritis. The authors concluded that only etanercept was within the acceptable cost-effectiveness thresholds defined

NHS Economic Evaluation Database.2007

115. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Walsh C A, Minnock P, Slattery C, Kennedy N, Pang F, Veale D J, Bresnihan B, FitzGerald (...) O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This 32-week study evaluated the switching of treatments in patients with rheumatoid arthritis (RA), from established and responsive infliximab therapy (at least 12 weeks

NHS Economic Evaluation Database.2007

116. Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials

Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials Kobelt G, Sobocki P, Sieper J (...) , Braun J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the treatment of ankylosing spondylitis (AS) with infliximab (5 mg/kg every 6 weeks) compared with standard treatment. Standard treatment was defined

NHS Economic Evaluation Database.2007

117. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis

Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Kaplan G G, Hur C, Korzenik J, Sands B E Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to determine if dose escalation of infliximab was cost-effective in comparison with adalimumab initiation after loss of response to infliximab in patients with Crohn’s disease. The authors concluded that dose escalation would yield more quality

NHS Economic Evaluation Database.2007

118. [Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature]

[Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature] Az infliximab terapia az arthritis psoriatica kezeleseben; a klinikai es az egeszseg-gazdasagtani szakirodalom attekintese [Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature] Az infliximab terapia az arthritis psoriatica kezeleseben; a klinikai es az egeszseg-gazdasagtani szakirodalom attekintese [Infliximab in patients (...) with arthritis psoriatic: systematic review of the clinical and economic literature] Brodszky V, Pentek M, Gulacsi L Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brodszky V, Pentek M, Gulacsi L. Az infliximab terapia az arthritis psoriatica kezeleseben; a klinikai es

Health Technology Assessment (HTA) Database.2007

119. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technology Assessment 2007; 11(28): 1-158 Authors' objectives "The objectives of this review were to assess the comparative clinical effectiveness

Health Technology Assessment (HTA) Database.2007

120. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness

Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis (...) and review of comparative clinical- and cost-effectiveness Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis

Health Technology Assessment (HTA) Database.2007